APRE (Aprea Therapeutics) Tariff Resilience Score: 7/10 (As of Jul. 01, 2026)


APRE Aprea Therapeutics Inc APRE
30 GF Score
Price $0.72
! 1 Warning Sign
View Full Analysis

What is Aprea Therapeutics Tariff Resilience Score?

Aprea Therapeutics APRE -7.07% 30 Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus rates APRE with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,374 Biotechnology companies, Aprea Therapeutics ranks better than 90.39% on this metric.

Aprea Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Aprea Therapeutics has Aprea Therapeutics has limited exposure to tariffs as its operations are primarily research-focused with minimal manufacturing dependencies. Its sales are not heavily reliant on international markets.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Aprea Therapeutics might have Highly Resilient.

Aprea Therapeutics  (NAS:APRE) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Aprea Therapeutics Tariff Resilience Score Related Terms

APRE vs JSPR, CVKD, BRTX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Aprea Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprea Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Aprea Therapeutics's Tariff Resilience Score falls into.


APRE
30GF Score
Aprea Therapeutics Inc APRE
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Aprea Therapeutics (APRE) has a Tariff Resilience Score of 7 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Aprea Therapeutics ranks #132 out of 1374 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Aprea Therapeutics' Tariff Resilience Score too high?
Aprea Therapeutics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Aprea Therapeutics' value of 7 is 75% above this industry median. Based on the distribution chart, Aprea Therapeutics ranks #132 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aprea Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aprea Therapeutics' Tariff Resilience Score compare to JSPR and CVKD?
According to the Biotechnology industry distribution chart, Aprea Therapeutics ranks #132 out of 1374 companies for Tariff Resilience Score. This places Aprea Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Aprea Therapeutics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aprea Therapeutics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprea Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprea Therapeutics stock overvalued right now?
Aprea Therapeutics (APRE) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Aprea Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Aprea Therapeutics (APRE), the current Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprea Therapeutics Business Description

Address 3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
30GF Score

Get the complete analysis for APRE

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price